Atomo Diagnostics Expands Point-of-Care Test Portfolio and Supply Partnerships

Atomo Diagnostics Ltd. ( (AU:AT1) ) has issued an update.

Atomo Diagnostics is sharpening its focus on building a high-value portfolio of point-of-care rapid tests, anchored by its market-leading HIV products in Australia, New Zealand and the U.K. and supported by in-development assays for active syphilis and liver function. The company is also deepening its role as a critical supply partner by providing proprietary cassettes to Lumos Diagnostics for the CLIA-waived FebriDx test and to NG Biotech for an IVDR-approved blood pregnancy test, while securing new customers that value its devices’ usability and reliability, underscoring growth prospects in global rapid testing markets.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Ltd., listed on the ASX as AT1, operates in the point-of-care diagnostics market, developing, manufacturing and supplying rapid tests, including self-tests, to international markets. Its portfolio focuses on best-in-class usability and reliability, with commercially launched HIV tests recognised as market leaders in Australia, New Zealand and the U.K., and strategic emphasis on expanding proprietary test cassettes and critical supply partnerships.

Average Trading Volume: 2,352,456

Technical Sentiment Signal: Sell

Current Market Cap: A$24.33M

For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.